Rare Daily Staff
Saniona, a clinical stage biotech company focused on rare diseases relating to eating disorders and the central nervous system, appointed Rami Levin as its CEO to lead the company’s transition to a fully-fledged biopharmaceutical company focused on rare diseases.
Saniona CEO Jørgen Drejer will remain with the company as its chief scientific officer.
“Rami has a proven track record in a number of areas critical to Saniona, including rare diseases, the U.S. regulatory and market access environment, and commercialization of innovative therapeutics that are of increasing importance to the company as we seek to bring our highly promising products to markets,” says J. Donald deBethizy, chairman of Saniona. “This is a natural point to step up development of the company, and we are looking forward to continue working with Jørgen in his role as CSO developing our pipeline.”
Levin comes to Saniona with more than 23 years of experience bringing rare disease and CNS treatments to market. Most recently he led Sobi’s push in the United States as president, North America for the Swedish drugmaker and its launch of Gamifant, the first ever approved treatment for primary hemophagocytic lymphohistiocytosis. Prior to that, he served in a number of roles at Merck Serono in the United States, Scandinavia, Switzerland, and Israel. Levin will be based in Boston.
“This is an important moment in the history of Saniona, as it aims to become a leading biotech company focusing on rare eating disorders and CNS diseases by developing new treatments that address significant unmet medical needs, both in-house and together with partners,” said Levin. “As part of this, our focus in the near-term will be the development and commercial opportunity for Tesomet in the rare eating disorders Prader-Willi Syndrome (PWS) and in Hypothalamic Obesity (HO), particularly in the U.S.”
Photo: Rami Levin, CEO of Saniona